Utah Medical Products (UTMD) Given Daily Coverage Optimism Rating of 0.08

Media stories about Utah Medical Products (NASDAQ:UTMD) have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Utah Medical Products earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 46.0474963837736 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

UTMD has been the topic of a number of research analyst reports. ValuEngine raised shares of Utah Medical Products from a “sell” rating to a “hold” rating in a report on Tuesday, June 6th. BidaskClub raised shares of Utah Medical Products from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th.

Shares of Utah Medical Products (NASDAQ:UTMD) opened at 73.60 on Wednesday. Utah Medical Products has a 12-month low of $56.30 and a 12-month high of $75.00. The firm’s 50-day moving average is $71.33 and its 200 day moving average is $66.98. The stock has a market capitalization of $273.72 million, a P/E ratio of 21.11 and a beta of 0.74.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 3rd. Investors of record on Friday, September 15th will be issued a $0.265 dividend. The ex-dividend date is Thursday, September 14th. This represents a $1.06 annualized dividend and a yield of 1.44%. Utah Medical Products’s payout ratio is 30.37%.

TRADEMARK VIOLATION NOTICE: “Utah Medical Products (UTMD) Given Daily Coverage Optimism Rating of 0.08” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/2887699/utah-medical-products-utmd-given-daily-coverage-optimism-rating-of-0-08.html.

About Utah Medical Products

Utah Medical Products, Inc (UTMD) is engaged in the business of producing medical devices that are disposable and for hospital use. The Company’s product categories include labor and delivery/obstetrics, including fetal monitoring accessories, Vacuum-Assisted Delivery Systems (VAD), and other labor and delivery tools; neonatal intensive care, including DISPOSA-HOOD, DELTRAN PLUS and GESCO; gynecology/urology/electrosurgery, including LETZ System, FINESSE+ Generator, EPITOME, PATHFINDER PLUS, HOLMIUM LASER FIBRES, LIBERTY System, ENDOCURETTE, TVUS/HSG-Cath and LUMIN, and blood pressure monitoring, including DELTRAN Disposable Pressure Transducer (DPT), and pressure monitoring accessories, components and other molded parts.

Insider Buying and Selling by Quarter for Utah Medical Products (NASDAQ:UTMD)

Receive News & Ratings for Utah Medical Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Utah Medical Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.